These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
698 related articles for article (PubMed ID: 26520640)
21. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Yu X; Sheng J; Pan G; Fan Y Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485 [TBL] [Abstract][Full Text] [Related]
22. Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer. She C; Wang R; Lu C; Sun Z; Li P; Yin Q; Liu Q; Wang P; Li W Thorac Cancer; 2019 Feb; 10(2):137-142. PubMed ID: 30485664 [TBL] [Abstract][Full Text] [Related]
23. Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401). Kawabe T; Yamamoto M; Sato Y; Yomo S; Kondoh T; Nagano O; Serizawa T; Tsugawa T; Okamoto H; Akabane A; Aita K; Sato M; Jokura H; Kawagishi J; Shuto T; Kawai H; Moriki A; Kenai H; Iwai Y; Gondo M; Hasegawa T; Yasuda S; Kikuchi Y; Nagatomo Y; Watanabe S; Hashimoto N J Neurosurg; 2016 Dec; 125(Suppl 1):11-17. PubMed ID: 27903179 [TBL] [Abstract][Full Text] [Related]
24. Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era. Cole KL; Earl ER; Findlay MC; Sherrod BA; Tenhoeve SA; Kunzman J; Cannon DM; Akerley W; Burt L; Seifert SB; Goldman M; Jensen RL J Neurooncol; 2024 Sep; 169(3):671-681. PubMed ID: 38951457 [TBL] [Abstract][Full Text] [Related]
25. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301 [TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status. Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150 [TBL] [Abstract][Full Text] [Related]
27. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients. Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711 [TBL] [Abstract][Full Text] [Related]
28. Gamma knife radiosurgery for treatment of cerebral metastases from non-small-cell lung cancer. Motta M; del Vecchio A; Attuati L; Picozzi P; Perna L; Franzin A; Bolognesi A; Cozzarini C; Calandrino R; Mortini P; di Muzio N Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e463-8. PubMed ID: 21530098 [TBL] [Abstract][Full Text] [Related]
29. Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies. Bauml J; Mick R; Zhang Y; Watt CD; Vachani A; Aggarwal C; Evans T; Langer C Clin Lung Cancer; 2013 Sep; 14(5):581-91. PubMed ID: 23827517 [TBL] [Abstract][Full Text] [Related]
30. Gamma knife radiosurgery for the management of cerebral metastases from non-small cell lung cancer. Bowden G; Kano H; Caparosa E; Park SH; Niranjan A; Flickinger J; Lunsford LD J Neurosurg; 2015 Apr; 122(4):766-72. PubMed ID: 25658792 [TBL] [Abstract][Full Text] [Related]
31. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. Tomasini P; Serdjebi C; Khobta N; Metellus P; Ouafik L; Nanni I; Greillier L; Loundou A; Fina F; Mascaux C; Barlesi F Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999344 [TBL] [Abstract][Full Text] [Related]
32. Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Flannery TW; Suntharalingam M; Regine WF; Chin LS; Krasna MJ; Shehata MK; Edelman MJ; Kremer M; Patchell RA; Kwok Y Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):19-23. PubMed ID: 18280058 [TBL] [Abstract][Full Text] [Related]
33. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711 [TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry. Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848 [TBL] [Abstract][Full Text] [Related]
35. Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer. Na YC; Jung HH; Kim HR; Cho BC; Chang JW; Park YG; Chang WS J Neurooncol; 2017 Apr; 132(2):333-340. PubMed ID: 28074321 [TBL] [Abstract][Full Text] [Related]
36. Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. Krawczyk P; Kowalski DM; Krawczyk KW; Szczyrek M; Mlak R; Rolski A; Szudy A; Kieszko R; Winiarczyk K; Milanowski J; Krzakowski M Oncol Rep; 2013 Sep; 30(3):1463-72. PubMed ID: 23783797 [TBL] [Abstract][Full Text] [Related]
37. Gamma knife radiosurgery in non small cell lung cancer patients with brain metastases: treatment results and prognostic factors. Abacioglu U; Caglar H; Atasoy BM; Abdulloev T; Akgun Z; Kilic T J BUON; 2010; 15(2):274-80. PubMed ID: 20658721 [TBL] [Abstract][Full Text] [Related]
38. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Lee HL; Chung TS; Ting LL; Tsai JT; Chen SW; Chiou JF; Leung HW; Liu HE Radiat Oncol; 2012 Oct; 7():181. PubMed ID: 23110940 [TBL] [Abstract][Full Text] [Related]
39. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159 [TBL] [Abstract][Full Text] [Related]
40. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated Non-small Cell Lung Cancer and Brain Metastases]. Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]